Skip to main content
. Author manuscript; available in PMC: 2010 Feb 18.
Published in final edited form as: Am J Psychiatry. 2008 Feb 15;165(4):459–467. doi: 10.1176/appi.ajp.2007.07091453

FIGURE 2.

FIGURE 2

Survival Curve Showing Time to Relapse for Children and Adolescents Receiving Fluoxetine or Placebo in Continuation Treatment After Response in Acute Treatment With Fluoxetine a

a Relapse was defined as either a one-time score ≥40 on the Children’s Depression Rating Scale—Revised (CDRS-R) with worsening of depressive symptoms for at least 2 weeks, or a clinician determination that significant clinical deterioration suggested that full relapse would be likely without altering treatment, even if the CDRS-R score was <40. The survival model was adjusted for the following covariates: gender, age, race, duration of episode, number of episodes, duration of illness, age at illness onset, and baseline continuation phase scores for the CDRS-R, Clinical Global Impression severity scale, Children’s Global Assessment Scale, and Family Global Assessment Scale.